Yeytuo

Yeytuo (lenacapavir) is a long-acting antiretroviral medication used in HIV treatment and prevention. It belongs to the capsid inhibitor class and is administered via subcutaneous injection. This overview covers key details for informed use.

Lenacapavir is primarily used to treat HIV-1 infection in adults and adolescents as part of combination therapy. It is also approved for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection in high-risk adults. The medication works by interfering with the virus’s lifecycle, helping to control viral load. It may be prescribed when other treatments are ineffective or unsuitable.

Lenacapavir helps reduce HIV viral load when used as directed, supporting immune function over time. Patients may experience improved energy levels and reduced symptoms associated with HIV as treatment progresses. The subcutaneous injection is designed for steady absorption, providing prolonged therapeutic effects. Individual responses vary based on adherence and medical history.

Lenacapavir should be stored as directed, typically refrigerated until use and kept at room temperature after injection. It is important to follow healthcare provider instructions for disposal of used injection materials. Patients with known allergies to lenacapavir or its components should avoid this medication. Regular medical monitoring is recommended during treatment.

Lenacapavir may interact with medications that affect liver enzymes, such as strong CYP3A inhibitors or inducers. Caution is advised when combining with other antiretrovirals or drugs metabolized by similar pathways. Alcohol and certain supplements may also influence effectiveness or side effects. Always inform your healthcare provider about all medications and supplements in use.